Phio Pharmaceuticals Commences Commercial‑Scale Production of Lead Candidate PH‑762

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology firm focused on cancer immunotherapy, announced that it has begun commercial‑scale production of its lead candidate, PH‑762. The company reported the initiation of manufacturing at a capacity sufficient to support future commercial distribution in the United States.

Key Details of the Milestone

  • Product: PH‑762, a therapeutic compound under development for oncological indications.
  • Production Scale: The facility has been upgraded to produce PH‑762 at a commercial volume, meeting the requirements for subsequent clinical supply and market launch.
  • Regulatory Status: The announcement follows the successful completion of Phase 1/2 clinical studies, indicating readiness for broader patient access pending regulatory approval.
  • Strategic Impact: Commercial‑scale production positions Phio Pharmaceuticals to transition from a development‑stage company to a commercial‑stage enterprise, potentially affecting the company’s valuation and investor perception.

Contextual Company Information

Phio Pharmaceuticals operates within the Health Care sector, specifically the Biotechnology industry. The company is listed on the Nasdaq exchange and trades in U.S. dollars. As of June 22, 2026, its share price closed at $1.04, with a 52‑week high of $4.19 (November 2, 2025) and a 52‑week low of $0.813 (February 4, 2026). The market capitalization stands at approximately $11.97 million. The company’s price‑earnings ratio is negative, reflecting its status as a development‑stage biopharmaceutical firm. Phio’s official website is www.phiopharma.com .

Implications for Stakeholders

  • Investors: The commencement of commercial production may improve the company’s cash‑flow prospects and provide a tangible milestone for valuation models that incorporate future revenue streams.
  • Patients and Clinicians: Availability of PH‑762 could expand therapeutic options for cancer patients once regulatory approvals are secured.
  • Industry Partners: The production scale may open avenues for collaboration or licensing agreements with other biopharmaceutical entities.

Source Statements

The information regarding the start of commercial‑scale production was reported by multiple financial news outlets on June 24, 2026, including www.investing.com , de.investing.com, and ceo.ca, all confirming the same development milestone.